Translational analyses of the DeCidE1clinical study in advanced ovarian cancer patients reveal a substantial role for B cells in the clinical benefit derived from maveropepimut-S (MVP-S) treatment

ESMO-IO, DECEMBER 2021

Translational analyses of the DeCidE1clinical study in advanced ovarian cancer patients reveal a substantial role for B cells in the clinical benefit derived from maveropepimut-S (MVP-S) treatment
Identification of potential response predictors to maveropepimut-S (DPX-Survivac), a novel T cell activating immunotherapy, in patients with advanced recurrent ovarian cancer

SITC, November 2021

Identification of potential response predictors to maveropepimut-S (DPX-Survivac), a novel T cell activating immunotherapy, in patients with advanced recurrent ovarian cancer
DPX-SurMAGE, a novel dual-targeted immunotherapy for bladder cancer, induces target-specific T cells with a favorable safety profile in preclinical model

AACR-NCI-EORTC, October 2021

DPX-SurMAGE, a novel dual-targeted immunotherapy for bladder cancer, induces target-specific T cells with a favorable safety profile in preclinical model
Survivin peptides formulated in the DPX delivery platform rather than standard emulsions, elicit a robust, sustained T cell response to survivin in advanced and recurrent ovarian cancer patients

AACR-NCI-EORTC, October 2021

Survivin peptides formulated in the DPX delivery platform rather than standard emulsions, elicit a robust, sustained T cell response to survivin in advanced and recurrent ovarian cancer patients

Scientific Reports, February 2021

Combination of a T cell activating therapy and anti-phosphatidylserine enhances anti-tumour immune responses in a HPV16 E7-expressing C3 tumour model

Brennan S. Dirk, Genevieve Weir, Tara Quinton, Olga Hrytsenko, Marianne M. Stanford

Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The SPiReL Study

ASH, DECEMBER 2020

Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The SPiReL Study

ONCOIMMUNOLOGY, NOVEMBER 2020

Quantitative MRI cell tracking of immune cell recruitment to tumors and draining lymph nodes in response to anti-PD-1 and a DPX-based immunotherapy

Marie-Laurence Tremblay, Zoe O’Brien-Moran, James A. Rioux, Andrea Nuschke, Christa Davis, W. Martin Kast, Genevieve Weir, Marianne Stanford & Kimberly D. Brewer

Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab

SITC, November 2020

Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab

OncoImmunology, June 2020

Generation of highly activated, antigen-specific tumor-infiltrating CD8+ T cells induced by a novel T cell-targeted immunotherapy, Vila-Leahey A, MacKay A , Portales-Cervantes L, Weir GM , Merkx-Jacques A, Stanford MM

Vila-Leahey A, MacKay A , Portales-Cervantes L, Weir GM , Merkx-Jacques A, Stanford MM

T cell infiltration into tumors induced by DPX-Survivac combination immunotherapy demonstrated by PET/MR imaging in an orthotopic ovarian cancer model

AACR, June 2020

T cell infiltration into tumors induced by DPX-Survivac combination immunotherapy demonstrated by PET/MR imaging in an orthotopic ovarian cancer model

Watch the presentation video